<ul><li>Researchers have developed an AI tool to predict which men with high-risk, non-metastatic prostate cancer will benefit from the drug abiraterone, unveiled at the American Society of Clinical Oncology’s annual meeting.</li><li>The new AI tool analyzes biopsy images to identify a biomarker indicating likely benefit from abiraterone and has shown to halve the five-year mortality rate for those with the biomarker.</li><li>This advancement could lead to more personalized treatment plans, improving outcomes, reducing unnecessary side effects, and potentially prompting revisions in treatment guidelines and drug approval policies.</li><li>Experts have praised the development for its potential to optimize personalized cancer care and enhance patient outcomes.</li></ul>

AI Breakthrough Personalizes Prostate Cancer Treatment

Discover more